Most evidence about this drug class answers one question at a time. A 2025 study in Veterans Affairs data did the opposite: it built a cohort of 215,970 people starting a GLP-1 and compared them against 159,465 starting sulfonylureas, 117,989 starting DPP4 inhibitors, 258,614 starting SGLT2 inhibitors, a mixed control group of 536,068 and a usual-care group of 1,203,097, then mapped associations across 175 outcomes at once [1]. It is the widest view available, and the width is both why it is useful and why it should be read carefully — more carefully than a head-to-head comparison needs to be.
What went down
Against usual care, GLP-1 use was associated with reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders including Alzheimer’s disease and dementia, coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions.
What went up
In the same analysis, GLP-1 use was associated with increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.
Two of those are worth a buyer’s attention specifically. Hypotension and syncope mean fainting, which matters if you drive for a living or work at height. And kidney stones and interstitial nephritis are the kind of thing a prescriber wants to know your history on — which assumes a prescriber who asks, and most sellers here publish nothing about what an intake covers.
Who these people were
The cohorts are US Veterans Affairs patients with diabetes — a population that is older, overwhelmingly male, and under continuous medical follow-up. Almost nothing about that resembles the person buying compounded semaglutide through a website, who is more often younger, more often female, frequently without diabetes, and typically seen once by a clinician they will never speak to again.
The comparison groups matter too. Everyone here was taking something for diabetes, so the contrast is GLP-1 against other diabetes drugs rather than against nothing. That is a fairer comparison than most observational work manages, and it is a different question from the one a first-time buyer is asking.
What survives into a purchase decision
Not much, directly — and that is the honest answer. What it does establish is the shape of the trade: broad benefit across several organ systems, alongside a real and specific list of things that get worse. Neither half of that is visible on a product page.
The practical version is the same as it always is here. Know what you are buying, know what it costs when the dose rises, and know how to reach someone. Our price distribution covers the first, the dose-pricing census covers the second, and the ranked board shows which sellers publish enough to answer the third.
Corpus figures on this site are computed at build time, most recently read September 2026. The outcome associations above are cited and are not this site’s own.